Professor Neil John Lloyd Gittoes BSc MB ChB PhD FRCP

• FRCP Royal College of Physicians 2004
• PhD Molecular Endocrinology, University of Birmingham 2008
• MRCP Royal College of Physicians 2003
• MBChB (Honours) Medicine and Surgery, University of Birmingham 1990
• BSc (Honours) Anatomical Studies, University of Birmingham, 1987

Professor Neil Gittoes leads the metabolic bone diseases unit in Birmingham, and a number of national work streams through the Royal Osteoporosis Society as Chair of the Board of Trustees and as National Clinical Lead for Specialised Endocrinology, NHSEI. Neil is member of the National Osteoporosis Guideline Group (NOGG); he works with NICE and was Clinical Lead for NICE Guideline on Primary Hyperparathyroidism (NG132) and instigated Rapid Evidence Summary for vitamin D in COVID-19 (ES28). He is member and co-chair of the International Taskforce and European PARAT programme on parathyroid disorders. He was honoured by the Royal College of Physicians and made Goulstonian Lecturer for his contributions to clinical research. He has published more than 150 papers, reviews and chapters across endocrinology, focussing on bone and mineral metabolism. His clinical research interests include models of fracture prevention, rare causes of fracture susceptibility and disorders of calcium homeostasis.

• Gittoes (PI)   09/19   09/2021  NIHR HTA Reference Number: NIHR127550 - The BLAST OFF (Bisphosphonate aLternAtive regimenS for the prevenTion of Osteoporotic Fragility Fractures) Study – “The study looks at how effective different bisphosphonate regimens are compared to Alendronate at preventing fractures, whether the reduction in fracture risk can be achieved at a reasonable financial cost and to establish the acceptability of different approaches to patients”.   £458,682 + £7174 NHS costs
• Gittoes (PI) 11/2018 , 07/2020, Shire Pharmaceuticals – “A Randomized, Double-blind, Placebo-controlled, Adaptive Study to Evaluate Symptom Improvement and Metabolic Control Among Adult Subjects With Symptomatic Hypoparathyroidism Treated With Recombinant Human Parathyroid Hormone [rhPTH(1-84)]”
• Gittoes (PI), 12/2018, 12/2020, Efficacy and Mechanism Evaluation and Eli Lilly – “Randomised Trial of Teriparatide followed by Zoledronic Acid versus standard care to prevent fractures in adults with Osteogenesis Imperfecta (TOPaZ)” 
• Gittoes (PI), 12/2018, Kyowa Kirin – “An international, multicentre, prospective, non-interventional observational registry for patients with X-linked hypophosphatemia (XLH)”
• Greig (PI) and Gittoes 09/2015, 08/2018, National Osteoporosis Society PhD studentship 3 years – “Influence of combined vitamin D supplementation and resistance exercise training on musculoskeletal health in frail older men and women (EXVITD)” £94,160
• Cooper (PI), Stewart, Eastell, Gittoes*, 10/2015, 09/2017, MRC-Astra Zeneca Co-funded translational research grant for staff and consumables 2 years - “Phase II study of the impact of a selective 11beta-HSD1 inhibitor on biochemical markers”. *Study subsequently moved to University of Leeds. Gittoes currently member of Safety Review Committee.  £311,707
• Wordsworth (CI), multiple co-Is, 05/2015, NIHR Rare Diseases Translational Research Collaboration & Oxford NIHR Musculoskeletal Biomedical Research Unit - “Rare diseases of the bone, joint and vessels Study (RUDY)”   £112,456
• Gittoes (PI), 12/2015, Alexion Pharmaceuticals “An observational, longitudinal, prospective, long-term registry of patients with hypophosphatasia”         
• Hiwot (PI) and Gittoes 12/2012, 11/2015, Shire Pharmaceuticals for post-doctoral fellow 3 years - “Understanding the molecular mechanism of bone disease in patients with Gaucher’s disease”    £195,000
• Doyle (PI), Gittoes, Tsesmelis, 11/2013, 12/2015, Older Adults Workforce Integration Board, Birmingham and Solihull 2 years “Falls and Fractures Prevention in Care Homes” £171,091
• Shepstone (CI), Cooper, Gittoes, Harvey, Heawood,  McCloskey, O’Neill, Peters, Torgerson (Co-PIs), 11/2006, 11/2015 (further extension planned)     MRC Health Technology Assessment Grant 7 years + extension “A pragmatic randomised controlled trial of screening for osteoporosis in older women”  Total research £4,280,273 +NHS costs £4,750,985

• Chair of the Board of Trustees, Royal Osteoporosis Society
• Chair, West Midlands Clinical Senate, NHSE
• National Clinical Lead, Specialised Commissioning of Endocrine Services, NHSE
• Medical Vice Chair, West Midlands Committee of the Advisory Committee on Clinical Impact Awards (ACCIA),  DHSC